$Beigene, _老虎社区_美港股上老虎

MingWeiK
2021-12-15

$Beigene, Ltd.(688235)$$Myovant Sciences Ltd.(MYOV)$MYOV now Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter and 20x better enterprise value vs EBITA ratio

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":607651093,"tweetId":"607651093","gmtCreate":1639535650131,"gmtModify":1639535666610,"author":{"id":3549446421753732,"idStr":"3549446421753732","authorId":3549446421753732,"authorIdStr":"3549446421753732","name":"MingWeiK","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/688235\">$Beigene, Ltd.(688235)$</a><a href=\"https://laohu8.com/S/MYOV\">$Myovant Sciences Ltd.(MYOV)$</a>MYOV now&nbsp;Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well&nbsp;below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter and 20x better enterprise value vs EBITA ratio</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/688235\">$Beigene, Ltd.(688235)$</a><a href=\"https://laohu8.com/S/MYOV\">$Myovant Sciences Ltd.(MYOV)$</a>MYOV now&nbsp;Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well&nbsp;below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter and 20x better enterprise value vs EBITA ratio</p></body></html>","text":"$Beigene, Ltd.(688235)$$Myovant Sciences Ltd.(MYOV)$MYOV now Trading below its IPO price when there was nothing… 2 blockbuster drugs approved and commercialization by Pfizer at tiered payment of 4.2billion for half the sales. Sales has started and growing steadily with good reviews from practicitors… One more drug pending approval and Sumi looking at acquiring the last “vant” company to make upfor the patent cliff made MYOV an irresitiable target to buy.. another contender will be Pfizer who is flooded with cash and out on a buying spree.. either one move and we will have a winner here… trading well below valuation at this price…Greatvalue at 3 times better price to sales ratio versus last quarter and 20x better enterprise value vs EBITA ratio","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607651093","repostId":0,"isVote":1,"tweetType":1,"viewCount":550,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["688235","MYOV"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":633,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}